MX2020007627A - Uso de la carrimicina o de sus ingredientes activos. - Google Patents
Uso de la carrimicina o de sus ingredientes activos.Info
- Publication number
- MX2020007627A MX2020007627A MX2020007627A MX2020007627A MX2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A
- Authority
- MX
- Mexico
- Prior art keywords
- isovalerylspiramycin
- active ingredient
- carrimycin
- iii
- drug
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 3
- GIDHDUYAXIVIMN-JJORJHTQSA-N CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC Chemical compound CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC GIDHDUYAXIVIMN-JJORJHTQSA-N 0.000 abstract 2
- PNMQDIDLWTXQLZ-RZELCZIWSA-N CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O Chemical compound CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O PNMQDIDLWTXQLZ-RZELCZIWSA-N 0.000 abstract 2
- GCIQAGXAZPUQNA-YDPAJNKASA-N CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C GCIQAGXAZPUQNA-YDPAJNKASA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un medicamento para prevenir y/o tratar una enfermedad, la enfermedad es enfermedad de Alzheimer, diabetes o senilidad; y el medicamento incluye un primer ingrediente activo, y el primer ingrediente activo incluye uno de carrimicina, isovalerilespiramicina I, isovalerilespiramicina II e isovalerilespiramicina III, o una combinación de dos o tres de isovalerilespiramicina I, isovalerilespiramicina II e isovalerilespiramicina III.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810052732 | 2018-01-19 | ||
| CN201810053060 | 2018-01-19 | ||
| CN201810052558 | 2018-01-19 | ||
| PCT/CN2019/072413 WO2019141256A1 (zh) | 2018-01-19 | 2019-01-18 | 可利霉素或其活性成分的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007627A true MX2020007627A (es) | 2020-11-24 |
Family
ID=67301318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007627A MX2020007627A (es) | 2018-01-19 | 2019-01-18 | Uso de la carrimicina o de sus ingredientes activos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11413302B2 (es) |
| EP (1) | EP3741373B1 (es) |
| JP (1) | JP7152052B2 (es) |
| KR (1) | KR20200112898A (es) |
| AU (1) | AU2019209740A1 (es) |
| CA (1) | CA3088823A1 (es) |
| MX (1) | MX2020007627A (es) |
| RU (1) | RU2771046C2 (es) |
| WO (1) | WO2019141256A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051845A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种mTOR抑制剂、药物组合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2765876B2 (ja) * | 1988-10-24 | 1998-06-18 | 科研製薬株式会社 | ピリジルケトオキシムエーテル誘導体 |
| CN1237976C (zh) * | 2003-12-23 | 2006-01-25 | 沈阳同联集团有限公司 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
| EP1720886A1 (en) | 2004-03-02 | 2006-11-15 | Wyeth | Macrolides and methods for producing same |
| DE602007006663D1 (de) | 2006-06-12 | 2010-07-01 | Univ Ramot | Verfahren zur behandlung von krebs |
| WO2011056961A2 (en) * | 2009-11-04 | 2011-05-12 | Health Research Inc. | Method and compositions for suppression of aging |
| CN101785779B (zh) | 2010-03-09 | 2014-03-05 | 沈阳同联集团有限公司 | 异戊酰螺旋霉素ii的分离制备 |
| CN101785778A (zh) | 2010-03-09 | 2010-07-28 | 沈阳同联集团有限公司 | 异戊酰螺旋霉素i的分离制备及其应用 |
| CN101773510B (zh) | 2010-03-09 | 2013-06-05 | 沈阳同联集团有限公司 | 异戊酰螺旋霉素iii的分离制备 |
| WO2011110084A1 (zh) | 2010-03-09 | 2011-09-15 | 沈阳同联集团有限公司 | 异戊酰螺旋霉素ⅰ、ⅱ或ⅲ的分离制备方法、及含有它们的药用组合物及其应用 |
| CA2800019C (en) | 2010-05-25 | 2015-05-26 | Shenyang Tonglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
| EP2578595B1 (en) * | 2010-05-25 | 2017-04-19 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Crystalline levoisovalerylspiramycin i |
| KR101271593B1 (ko) | 2010-07-16 | 2013-06-11 | 대우제약 주식회사 | 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항혈관신생효과를 갖는 조성물 |
| EP2884967B1 (en) * | 2012-08-16 | 2017-02-01 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of memantine |
| JP6154026B2 (ja) | 2012-12-31 | 2017-06-28 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | Ｐｄｅ４阻害活性を有する選ばれたマクロライド |
| RU2746047C1 (ru) | 2017-04-06 | 2021-04-06 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Применение карримицина и его фармацевтически приемлемой соли для производства медикаментов для лечения и/или профилактики опухоли |
| RU2766176C2 (ru) | 2017-07-04 | 2022-02-08 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата |
| CN110051845A (zh) | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种mTOR抑制剂、药物组合物及其应用 |
-
2019
- 2019-01-18 MX MX2020007627A patent/MX2020007627A/es unknown
- 2019-01-18 RU RU2020126396A patent/RU2771046C2/ru active
- 2019-01-18 KR KR1020207023822A patent/KR20200112898A/ko not_active Ceased
- 2019-01-18 JP JP2020539282A patent/JP7152052B2/ja active Active
- 2019-01-18 AU AU2019209740A patent/AU2019209740A1/en not_active Abandoned
- 2019-01-18 US US16/962,592 patent/US11413302B2/en active Active
- 2019-01-18 WO PCT/CN2019/072413 patent/WO2019141256A1/zh not_active Ceased
- 2019-01-18 CA CA3088823A patent/CA3088823A1/en active Pending
- 2019-01-18 EP EP19741498.0A patent/EP3741373B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3741373A4 (en) | 2021-03-10 |
| EP3741373B1 (en) | 2022-10-12 |
| CA3088823A1 (en) | 2019-07-25 |
| RU2771046C2 (ru) | 2022-04-25 |
| US20200338107A1 (en) | 2020-10-29 |
| JP7152052B2 (ja) | 2022-10-12 |
| US11413302B2 (en) | 2022-08-16 |
| JP2021517887A (ja) | 2021-07-29 |
| EP3741373A1 (en) | 2020-11-25 |
| WO2019141256A1 (zh) | 2019-07-25 |
| RU2020126396A3 (es) | 2022-02-21 |
| AU2019209740A1 (en) | 2020-09-10 |
| RU2020126396A (ru) | 2022-02-21 |
| KR20200112898A (ko) | 2020-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| JOP20220092A1 (ar) | جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| EP4596041A3 (en) | Farnesoid x receptor agonists and uses thereof | |
| WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| BR112018003870A2 (pt) | construções cirúrgicas tubulares incluindo material auxiliar | |
| MX2020008017A (es) | Formulaciones de vidrio y usos de las mismas. | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| EP4427815A3 (en) | Deuterium-enriched pirfenidone and methods of use thereof | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| EP4570317A3 (en) | Compounds for the treatment of bovine or swine respiratory disease | |
| NZ801473A (en) | Lactam-modified polypeptide compounds | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| WO2021023069A8 (zh) | Tpk作为靶点在阿尔茨海默病的应用 | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| EP4461361A3 (en) | Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| EP4467138A3 (en) | Therapeutic agents for neurodegenerative diseases | |
| EP3795170A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE |